hiPSC-Derived Neurons for Faster Drug Discovery

Thursday, November 26th at 15:00 GMT | 16:00 CET | 10:00 EST | 07:00 PST

Drug discovery runs on human-relevant data — and in neuroscience, where primary material is hard to come by, that need is even more acute. Yet reaching the right model still takes too long.

Differentiation timelines can slow down early research and reaching the right terminal cell type often requires internal resources for optimization, and validation. Assay performance can vary across readouts, and for complex CNS biology, one generic neuronal model is rarely enough.

For these models to be useful in real discovery workflows, access to cells is only the starting point. For drug discovery pipelines to benefit, cells need to be assay-ready, relevant to the biology being studied, and supported by performance data across the applications that matter.

This webinar demonstrates how Ncardia’s human iPSC-derived neurons can support faster access to terminal cell types, reliable performance across assay formats, and better alignment between neuronal model selection and your discovery goals.

Key learning objectives

• Reducing time from model selection to experiment with assay-ready human iPSC-derived neurons
• Use terminal cell type access as a lever for more efficient neuroscience drug discovery workflows
• Evaluate neuronal model performance across relevant assay formats that matter to you
• Match neuronal subtype to disease biology and discovery objectives
• Case study to assess functional relevance and support early discovery decisions

Join this webinar if you’re part of a team looking to improve the speed, relevance, and reliability of your neuro discovery workflows with human iPSC-derived neuronal models.

Who should attend?

This webinar is most relevant for pharma and biotech teams working in neuro drug discovery,
CNS research, neurodegeneration, disease modeling, target validation, screening, and
translational assay development and toxicity/safety assessment.

Especially relevant for: R&D leaders, discovery scientists, assay development teams,
translational scientists, and platform teams evaluating human iPSC-derived neuronal models for
functional drug discovery applications.

Speakers

Shushnat Jain, PhD, directs Ncardia's drug discovery team, helping develop biological phenotypic assays in representative model systems to improve the translation of therapeutic strategies. He brings a rich diversity of expertise to his Ncardia role, having led large, multi-year research programs to aid several drug discovery initiatives spanning numerous therapeutic areas through the use of automation and high-content methodologies. He has managed, mentored, and trained scientists of all levels, both as a scientist and manager. Shushant's research has been published in Neuron, Genome Biology, the Journal of Biomolecular Screening, and the Journal of Biological Chemistry, among others.